Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL2847 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL13501651 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL556754 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL628757 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6268460 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL23468028 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2848 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL678274 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2849 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL4295454 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007039784-A2 | A NOVEL CRYSTALLINE POLYMORPH OF FLUVASTATIN SODIUM AND PROCESS FOR PREPARING IT | WOCKHARDT LIMITED (IN) | 2007-04-12 | — | — | WO | claimed |
| EP-1634870-A1 | Process and intermediates for the selective synthesis of Fluvastatin | Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) | 2006-03-15 | — | — | EP | claimed |
| WO-2005019170-A1 | NOVEL PROCESS FOR PREPARATION OF 7-[3-(4-FLUOROPHENYL)-1-(1-METHYLETHYL)-1H-INDOL-2-YL]-3, 5-DIHYDROXY-6-HEPTENOIC ACID SODIUM SALT | BIOCON LIMITED (IN) | 2005-03-03 | — | — | WO | claimed |
| US-20220184058-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AORTIC ANEURYSM | NATIONAL UNIVERSITY CORPORATION HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) | 2022-06-16 | — | — | US | disclosed |
| US-10500241-B2 | Compositions comprising Siraitia grosvenori extracts and methods for the treatment of infection | CASCADE ESTATES LIMITED (MU) | 2019-12-10 | — | — | US | disclosed |
| US-20180318370-A1 | COMPOSITIONS COMPRISING SIRAITIA GROSVENORI EXTRACTS AND METHODS FOR THE TREATMENT OF INFECTION | AMALFI ADVISORS LLC (MU) | 2018-11-08 | — | — | US | disclosed |
| US-20150231190-A1 | COMPOSITIONS COMPRISING SIRAITIA GROSVENORI EXTRACTS AND METHODS FOR THE TREATMENT OF INFECTION | CASCADE ESTATES LTD (MU) | 2015-08-20 | — | — | US | disclosed |
| WO-2015024925-A1 | MODULATORS OF THE UNCONVENTIONAL SECRETORY PATHWAY FOR USE IN THE TREATMENT OF ALEXANDER DISEASE | RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN (DE) | 2015-02-26 | — | — | WO | disclosed |
| EP-1719525-B1 | Nuclear transfer promoter for cdc42 protein and method of screening the same | KOWA CO (JP) | 2014-12-10 | — | — | EP | disclosed |
| EP-1719524-B1 | NUCLEAR TRANSFER PROMOTER FOR RAC PROTEIN AND METHOD OF SCREENING THE SAME | KOWA CO (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-8637274-B2 | Inhibitor for the formation of gamma-secretase complex | KOWA COMPANY, LTD. (JP) | 2014-01-28 | — | — | US | disclosed |
| US-6811786-B1 | MIXED WITH BIFIDOGENIC OLIGOSACCHARIDE; INCREASING HIGH DENSITY LIPOPROTEINS | GANEDEN BIOTECH, INC. | 2004-11-02 | — | — | US | disclosed |
| EP-1399466-A2 | COMPOUNDS AND METHODS FOR THE MODULATION OF CD154 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| CN-1473151-A | Crystalline forms of fluvastatin sodium | �������⻯ѧƷ�ع�����˾ | 2004-02-04 | — | — | CN | disclosed |
| US-20030195167-A1 | PTX3-gene expression inhibitor | KOWA CO., LTD. (JP) | 2003-10-16 | — | — | US | disclosed |
| EP-1314423-A1 | MEDICINAL COMPOSITIONS | Sankyo Company, Limited (JP) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002089730-A2 | COMPOUNDS AND METHODS FOR THE MODULATION OF CD154 | THE CENTER FOR BLOOD RESEARCH, INC. (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1067945-A2 | METHODS FOR REDUCING CHOLESTEROL USING BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS | Ganeden Biotech, Inc. (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999049877-A2 | METHODS FOR REDUCING CHOLESTEROL USING BACILLUS COAGULANS SPORES, SYSTEMS AND COMPOSITIONS | GANEDEN BIOTECH, INC. (US) | 1999-10-07 | — | — | WO | disclosed |
| US-4929437-A | Coenzyme Q10 with HMG-CoA reductase inhibitors | MERCK & CO., INC. (US) | 1990-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231190-A1 | COMPOSITIONS COMPRISING SIRAITIA GROSVENORI EXTRACTS AND METHODS FOR THE TREATMENT OF INFECTION | CD4, GYS2, GANC | HMGCR 53/4885CYP2C9 125/4885SIRT6 1769/4885 |
| US-20180318370-A1 | COMPOSITIONS COMPRISING SIRAITIA GROSVENORI EXTRACTS AND METHODS FOR THE TREATMENT OF INFECTION | GYS2, CD4, GANC | HMGCR 52/4885CYP2C9 127/4885SIRT6 1737/4885 |
| US-20030195167-A1 | PTX3-gene expression inhibitor | CCR3, CFH, SERPINH1 | HMGCR 1909/4885CYP2C9 4521/4885SIRT6 3039/4885 |
| US-10500241-B2 | Compositions comprising Siraitia grosvenori extracts and methods for the treatment of infection | GYS2, CD4, GANC | HMGCR 52/4885CYP2C9 127/4885SIRT6 1737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.